10-Q · May 15, 2026
In Q1 2026, China Pharma Holdings reported a revenue of $980,000, a decrease from $1.14 million in Q1 2025 due to market competition and changes in procurement policies. Gross margin improved significantly from a loss…
Earnings analysis · 10-Q
CPHI earnings analysis
Filed August 14, 2026 · Our reading of the company's report
The latest report
The supplied filing text does not include current-quarter revenue, EPS, margins, cash flow, balance-sheet amounts, or segment results, so operating trends cannot be assessed from the filing excerpt. The principal…
Read full summary
The supplied filing text does not include current-quarter revenue, EPS, margins, cash flow, balance-sheet amounts, or segment results, so operating trends cannot be assessed from the filing excerpt. The principal disclosed development is that disclosure controls remained ineffective as of June 30, 2026 because of an accounting personnel-related material weakness previously reported in the December 31, 2025 Form 10-K. No quantitative operating guidance was provided.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Financial statements deemed fairly stated
Management evaluated disclosure controls as of June 30, 2026 and concluded they were not effective. The filing states that the condensed consolidated financial statements were nevertheless fairly stated in all material respects under U.S. GAAP.
What to watch
-
Material weakness remains unresolved
Disclosure controls remained ineffective as of June 30, 2026 because of a material weakness related to the lack of accounting and financial-reporting personnel knowledgeable in U.S. GAAP. Management states this weakness was previously disclosed in the Form 10-K for the year ended December 31, 2025.
-
Limited market-risk disclosure
The filing states that the company is a smaller reporting company and is not required to provide the market-risk disclosures under Item 3. As a result, quantitative exposure to market risks is not presented in this report.
Management's outlook
No quantitative revenue, EPS, margin, or operating outlook was provided in the supplied filing text.
Earlier filings 4
10-K · April 1, 2026
China Pharma positions itself as a China-focused manufacturer of generics and modern TCMs with rights to manufacture 19 products and two GMP-compliant production facilities (20,282.42 sqm and 6,593.20 sqm buildings).…
10-Q · August 14, 2025
China Pharma reported Q2 2025 revenue of $1,025,767 (up from $924,943 a year ago) and a net loss of $528,367 (EPS $(0.16)), with meaningful year‑over‑year margin improvement but continued operating losses and material…
10-Q · August 14, 2024
China Pharma reported Q2 revenue of $924,943, down from $1,097,862 in Q2 2023, with a Q2 net loss of $1,438,130 and EPS of $(0.09). Gross loss widened to $(1,015,386) and operating loss to $(1,391,521), while cash…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.